KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Weighted Average): 2011-2024

Historic Shares Outstanding (Weighted Average) for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $55.2 million.

  • Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.76% to $56.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.1 million, marking a year-over-year increase of 1.76%. This contributed to the annual value of $55.2 million for FY2024, which is 1.07% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Shares Outstanding (Weighted Average) of $55.2 million as of FY2024, which was up 1.07% from $54.6 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $55.2 million during FY2024, and registered a low of $52.7 million during FY2020.
  • In the last 3 years, Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $54.6 million in 2023 and averaged $54.6 million.
  • Data for Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY rose of 1.65% (in 2022) over the last 5 years.
  • Over the past 5 years, Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $52.7 million in 2020, then increased by 0.94% to $53.2 million in 2021, then grew by 1.65% to $54.1 million in 2022, then climbed by 1.06% to $54.6 million in 2023, then climbed by 1.07% to $55.2 million in 2024.